Ownership and insider activity for PTC Therapeutics, Inc. (PTCT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
Price
| Price | $63.65 |
| Market Cap | $5.3B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-30 | STEELE GLENN JR MD PHD | M-Exempt | 12,000 | $135K |
| 2026-09-30 | STEELE GLENN JR MD PHD | S-Sale | 12,000 | $782K |
| 2026-09-30 | STEELE GLENN JR MD PHD | M-Exempt | 12,000 | $135K |
| 2026-09-16 | SCHMERTZLER MICHAEL | S-Sale | 2,994 | $199K |
| 2026-09-16 | SCHMERTZLER MICHAEL | S-Sale | 7,006 | $472K |
| 2026-09-17 | SCHMERTZLER MICHAEL | S-Sale | 9,624 | $653K |
| 2026-09-17 | SCHMERTZLER MICHAEL | S-Sale | 376 | $26K |
| 2026-09-09 | SCHMERTZLER MICHAEL | S-Sale | 9,428 | $639K |
| 2026-09-09 | SCHMERTZLER MICHAEL | S-Sale | 572 | $39K |
| 2026-09-10 | SCHMERTZLER MICHAEL | S-Sale | 10,000 | $673K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $231.7M | $191.2M | $227.6M | $288.0M | $208.8M | $189.7M | $279.8M | $594.0M | $779.7M | $984.6M |
| Short-term Investments | 0 | 0 | 0 | $398.5M | $894.8M | $583.7M | $130.9M | $282.7M | $360.0M | $960.7M |
| Receivables | $24.9M | $40.4M | $67.9M | $55.5M | $69.9M | $110.5M | $155.6M | $160.8M | $158.6M | $181.6M |
| Inventory | 0 | $10.8M | $16.1M | $19.3M | $18.7M | $15.9M | $21.8M | $30.6M | $23.2M | $79.6M |
| Total Current Assets | $261.3M | $249.1M | $320.9M | $779.3M | $1.23B | $954.4M | $693.8M | $1.22B | $1.37B | $2.27B |
| Property, Plant & Equipment | $7.4M | $8.4M | $12.7M | $35.2M | $118.2M | $130.0M | $175.0M | $179.0M | $117.7M | $135.4M |
| Goodwill | 0 | 0 | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M |
| Intangible Assets | 0 | $133.0M | $701.0M | $710.5M | $715.3M | $724.8M | $705.9M | $379.5M | $118.8M | $388.8M |
| Total Assets | $269.3M | $391.7M | $1.12B | $1.62B | $2.21B | $1.94B | $1.71B | $1.90B | $1.71B | $2.90B |
| Accounts Payable | $6.3M | $15.3M | $6.0M | $10.3M | $18.7M | $23.0M | $27.3M | $6.0M | $17.3M | $45.5M |
| Short-term Debt | 0 | 0 | $11.7M | $20.0M | 0 | $208.8M | $72.1M | $194.3M | $257.8M | $569.6M |
| Total Current Liabilities | $49.6M | $82.0M | $166.8M | $235.9M | $277.3M | $509.3M | $406.2M | $603.1M | $581.0M | $968.4M |
| Long-term Debt | $98.2M | $145.0M | $141.3M | $293.9M | $309.1M | $956.6M | $1.26B | $1.90B | $2.11B | $2.03B |
| Total Liabilities | $149.8M | $235.2M | $768.5M | $1.03B | $1.73B | $1.94B | $2.05B | $2.71B | $2.80B | $3.10B |
| Retained Earnings | -$735.1M | -$814.1M | -$938.9M | -$1.19B | -$1.63B | -$2.10B | -$2.66B | -$3.28B | -$3.65B | -$2.96B |
| Total Equity | $119.6M | $156.4M | $350.7M | $594.3M | $482.0M | $1.4M | -$347.1M | -$818.6M | -$1.10B | -$205.3M |
| Total Debt | $98.2M | $145.0M | $153.0M | $328.0M | $420.4M | $1.27B | $1.46B | $2.23B | $2.47B | $2.71B |
| Net Debt | -$133.4M | -$46.3M | -$74.6M | -$358.5M | -$683.2M | $496.0M | $1.05B | $1.35B | $1.33B | $761.7M |
| Working Capital | $211.7M | $167.0M | $154.1M | $543.4M | $954.4M | $445.0M | $287.5M | $615.5M | $784.5M | $1.31B |
Financial Health
| Debt / Equity | -13.19 |
| Current Ratio | 2.35 |
Profitability
| Return on Equity | -332.49% |
| Return on Invested Capital | 33.37% |
| Return on Assets | 23.55% |
| Gross Margin | 95.85% |
| Operating Margin | 49.49% |
| Net Margin | 39.44% |
Related companies: ALKS · ARWR · KRYS · MTSR · PCVX
Explore sector: Healthcare · Biotechnology
More sections of PTCT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks